Edgen Stock·Sep 09 2025, 09:06戻る
戻る
Regenxbio: RGX-121 FDA Review Extended Amidst Robust Clinical Data and Investor Confidence
Edgen Stock·Sep 09 2025, 09:06
[1] Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome[2] Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) | Seeking Alpha[3] Agios Pharmaceuticals and the FDA Delay for Pyrukynd in Thalassemia: Assessing the Materiality of Safety Concerns and REMS Submission on Commercial Potential and Stock Valuation - AInvest